30-Oct-2020 | Market Research Store
Coronavirus pandemic has taken the entire world by a world storm as a permanent cure and means to resist the virus has not yet been found. Currently, the medical professionals have tried many therapies and existing drugs to inhibit the spread of the virus in COVID-19. Researchers have found remdesivir and dexamethasone to be the only drugs that have hastened COVID-19 recovery. It is remdesivir that has been approved by the FDA as a drug for curing COVID-19. Additionally, the blood thinners are also used in coronavirus therapies in order to stop blood clotting that affectvarious organs. On the other hand, the drugs like hydroxychloroquine werenot as promising as remdesivir.
A team from Spain has found a new drug to treat coronavirus and it is Aplidin (plitidepsin). This drug is basically used to treat cancer. The antiviral effects of the drug make it a suitable candidate for preventing coronavirus from infecting other cells. It is clear that the plitidepsin can help significantly reduce recovery time and help hospitals manage the increasing cases of COVID-19. The drug has reached Phase 3 trial. Moreover, the drug has shown the ability to bind to a human protein,EF1A, which the virus uses to replicate.The rapid proliferation of the virus can be prevented in the early days. Earlier the drug was synthesized from Aplidium Albicansspecies but it is being developed synthetically.
The basic goal was to reduce the multiplication rate, lower viral load to avoid the sequelae faced by COVID-19 sufferers’ months after. The resurgence of the virus is currently being faced by many nations across the globe. Plitidepsin showed better inhibition of replication compared to remdesivir. The Barcelona Supercomputing Center (BSC-CNS), IrsiCaixa, and CReSA found plitidepsin to have the toughest antiviral activity against the coronavirus.
Market Research Store has published a report on global human-respiratory-syncytial-virus drugs market. The report covers all the qualitative and quantitative factors of the market.